← Research ProtocolsCJC-1295 + DAC
STUDIED EXPOSURE MAP / 2006
CJC-1295 + DAC
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / PK + PDJ CLIN ENDOCRINOL METABSTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
30 µg/kg
single SC exposure; repeated cohorts also studied
60 µg/kg
single SC exposure; repeated cohorts also studied
125 µg/kg
single SC exposure
250 µg/kg
single SC exposure
Context: The publication reports single-dose cohorts across 30–250 µg/kg and additional weekly/biweekly repeat-dose cohorts. This is pharmacology, not an efficacy protocol.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / J CLIN ENDOCRINOL METAB
Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2006
01 / DESIGNTwo randomized · placebo-controlled · double-blind · ascending-exposure studies
02 / POPULATION / MODELHealthy adults
03 / ROUTESubcutaneous
04 / TIMEFRAME28-day and 49-day studies
05 / PRIMARY QUESTIONPK, GH, IGF-1 and safety
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Longer-acting GHRH analogue research
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.